The A4 study is underway to see if an experimental drug can protect healthy seniors whose brains harbor silent signs that they’re at risk. On June 9, a Rhode Island man was hooked up for an IV infusion at Butler Hospital in Providence, the first treated. The $140 million study, funded by the National Institutes of Health, Eli Lilly & Co., and others, will track if participants’ memory and amyloid levels change over three years. The study is enrolling participants at more than 60 sites, including the Penn Memory Center. In an AP article published in June, Dr. Jason Karlawish, Associate Director of the Penn Memory Center, and a designer of the study’s psychological precautions, calls the research “an opportunity to study the future of the way we’re going to think about, talk about and live with the risks of Alzheimer’s disease.” You can read the AP article here.
You are here: / / A4 Trial Begins; First Patient Receives Infusion in Providence, RI